Mailed DNA tests could help families catch cancer early

NCT ID NCT06284330

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 35 times

Summary

This study tested a simple idea: send at-home genetic testing kits directly to relatives of people who have a hereditary cancer gene. The goal was to see if this approach gets more relatives tested compared to usual care. The study involved 108 adults in Texas who had a cancer-related gene mutation, and their adult relatives. Results will show whether mailing kits boosts testing rates and family communication about genetic risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Direct mailed at-home genetic testing kit

What this could lead to

If successful, this approach could help more at-risk relatives get tested for hereditary cancer genes, potentially leading to earlier detection and prevention.

What could go wrong

This is a small feasibility study (108 participants) that only looked at whether relatives got tested, not long-term health outcomes. Results may not apply to other populations or settings.

Conditions

The condition(s) this trial relates to.

hereditary neoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.